Screening for NNRTIs with slow dissociation and high affinity for a panel of HIV-1 RT variants

Journal of Biomolecular Screening

Volumn 14, Issue 4, 2009, Pages 395-403

  Elinder, Malin ^a   Nordström, Helena ^a   Geitmann, Matthis ^a   Hämäläinen, Markku ^b   Vrang, Lotta ^c   Öberg, Bo ^c   Danielson, U Helena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b GE Healthcare Bio Sciences AB   (Sweden)

^c MEDIVIR AB   (Sweden)

Author keywords

HIV 1 reverse transcriptase; Microbicides; NNRTIs; Screening; Surface plasmon resonance (SPR) biosensor

Indexed keywords

ENZYME VARIANT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MIV 170; MSC 197; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BIOSENSOR; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING SITE; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION;

BINDING, COMPETITIVE; BIOSENSING TECHNIQUES; ENZYMES, IMMOBILIZED; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MUTANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 65449134780     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057109333977     Document Type: Article

References (14)

1. Lederman MM, Offord RE, Hartley O.: Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 2006 ; 6: 371-382.
2. Cohen J.: AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 2007 ; 318: 28-29.
3. Walker BD, Burton DR: Toward an AIDS vaccine. Science 2008 ; 320: 760-764.
4. van de Wijgert JH, Shattock RJ: Vaginal microbicides: moving ahead after an unexpected setback. AIDS 2007 ; 21: 2369-2376.
5. Huber W.: A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions. J Mol Recognit 2005 ; 18: 273-281.
6. Andersson K., Karlsson R., Löfs S., Franklin G., Hämäläinen MD: Label-free kinetic binding data as a decisive element in drug discovery. Exp Opin Drug Discovery 2006 ; 1: 409-437.
7. Geitmann M., Unge T., Danielson UH: Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance. J Med Chem 2006 ; 49: 2375-2387.
8. Bhikhabhai R., Carlsson T., Unge T., Lövgren S., Strandberg B.: Increased yield of homogeneous HIV-1 reverse transcriptase (p66/p51) using a slow purification approach. J Chromatogr 1993 ; 639: 67-74.
9. Högberg M., Sahlberg C., Engelhardt P., Noreen R., Kangasmetsa J., Johansson NG, et al. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors: 3. Synthesis and further structure-activity relationship studies of PETT analogues. J Med Chem 1999 ; 42: 4150-4160.
10. Harada S., Yamamoto N.: Quantitation of and neutralizing antibodies to AIDS-retroviruses; a novel system using HTLV-I carrying MT-4 cells [in Japanese]. Tanpakushitsu Kakusan Koso 1985 ; 30: 1394-1407.
11. Weislow OS, Kiser R., Fine DL, Bader J., Shoemaker RH, Boyd MR: New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst 1989 ; 81: 577-586.
12. Hann MM, Oprea TI: Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 2004 ; 8: 255-263.
13. Nordström H., Gossas T., Hämäläinen M., Källblad P., Nyström S., Wallberg H., et al. Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. J Med Chem 2008 ; 51: 3449-3459.
14. Ren J., Stammers DK: Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res 2008 ; 134: 157-170.